IHS Chemical Week

People & Business :: Companies

AstraZeneca’s MedImmune Bid Queried

1:17 PM MDT | July 25, 2007 | Chemical Week Editorial Staff

Shareholders at AstraZeneca’s annual meeting last week raised concerns about the firm’s recent $58/share offer to purchase biotechnology firm MedImmune (Gaithersburg, MD). AstraZeneca’s offer values MedImmune at $15.6 billion and represents a 21% premium over MedImmune’s closing share price on April 20, three days before the bid was announced. Shareholders at the meeting questioned whether the proposed deal is “an act of desperation.” AstraZeneca has been hit by a string of drug candidate failures of late and these may have...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa